Adjuvant treatment of gastrointestinal stromal tumors (GIST)—state of the art, controversies, and future directions
Authors
Discussion
Loading...
Member takes
Implication
Literature review reveals recurrence-free survival gains from adjuvant imatinib in high-risk GIST, highlighting ongoing debates over treatment duration.
Key Points
- Synthesize current evidence, clinical controversies, and emerging strategies regarding risk stratification, mutational profiling, and adjuvant imatinib duration in resected gastrointestinal stromal tumors (GISTs).
- Conducted a comprehensive literature search across PubMed and major oncology congress databases for English-language publications on localized GISTs.
- Synthesized findings with priority given to randomized phase II/III clinical trials, pivotal observational studies, and international clinical guidelines.
- Three years of adjuvant imatinib serves as the standard of care for high-risk localized GISTs, substantially extending recurrence-free survival, though overall survival benefits remain limited.
- KIT exon 11 mutations demonstrate the highest therapeutic sensitivity to imatinib, while exon 9 mutations, non-KIT/PDGFRA tumors, and tumor rupture present distinct biological risks requiring tailored approaches.
- Recurrence frequently follows treatment cessation in very high-risk subsets, and while extended therapy beyond three years improves progression-free survival in select patients, clear overall survival improvements remain unproven.
Cite This Study
A.-M. et al. (2026) studied this question.